Skip to main content

AMPH

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

AMPH Price
Price Chart

Forward-looking statistics

Beta
0.81
Risk
39.42%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focusesĀ on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees1K
Market cap$2.0B

Fundamentals

Enterprise value$1.5B
Revenue$730.7M
Revenue per employee—
Profit margin19.38%
Debt to equity86.86

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$2.76
Dividend per share—
Revenue per share$15.13
Avg trading volume (30 day)$10M
Avg trading volume (10 day)$11M
Put-call ratio—

Macro factor sensitivity

Growth+3.5
Credit+12.7
Liquidity-5.0
Inflation-0.1
Commodities+1.1
Interest Rates-1.2

Valuation

Dividend yield0.00%
PEG Ratio5.31
Price to sales1.50
P/E Ratio5.31
Enterprise Value to Revenue2.05
Price to book1.47

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend day—

News

Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $1.04 per share a year ago.

Zacks Investment Research (May 7, 2025)
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds

On Thursday, Amphastar Pharmaceuticals Inc. AMPH reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, but missing the consensus of 94 cents.

Benzinga (February 28, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free